This study was conducted to evaluate the renoprotective effect of aliskiren-pentoxifylline combination and compare it with enalapril and valsartan in patients with hypertension, type 2 diabetes mellitus and diabetic nephropathy (DN). Sixty patients with hypertension, type 2 diabetes mellitus and microalbuminurea (20-200µg/min or 30-300mg/24h) were selected from UNRWA and private clinics in Gaza Strip and divided into three groups. The first group (n=20) was treated with enalapril (10-20mg/day), the second group (n=20) was treated with valsartan (160mg/day), whereas the third group (n=20) was treated with aliskiren-pentoxifylline combination (150,400mg/day). All patients were followed-up for nine months by measuring serum creatinine level and urinary albumin excretion (UAE) rate before and at 3, 6 and 9 months of treatment. Paired T-test and independent T-test were used to analyze our results and the significance was tested at p≤ 0.05. The results showed a significant reduction in both UAE rate and serum creatinine level among patients who used aliskirenpentoxifylline combination after 6 and 9 months of treatment, where the reduction was highly significant after 9 months of treatment (p=0.001 for UAE, p=0.000 for serum creatinine level). In the valsartan treated group, the reduction in UAE rate was significant (p=0.045) after 9 months of treatment, while no significant reduction was noticed in serum creatinine level (p=0.807). Moreover, no significant reduction was seen in UAE rate (p=0.125) and serum creatinine level (p=0.445) among patients who were given enalapril. In conclusion, aliskirenpentoxifylline combination showed renoprotective effect more distinct than enalapril and valsartan among patients with DN.
INTRODUCTION
Diabetes mellitus (DM) is a metabolic disorder of multiple causes characterized by chronic hyperglycemia and disorders of carbohydrate, fat, and protein metabolism owing to defects in insulin secretion, insulin action or combination of both factors 1, 2 . Diabetic nephropathy (DN) is considered as one of the major complications of DM which can develop in more than 40% of patients with DM [2] [3] [4] . It is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli due to longstanding DM 5 . Moreover, DN is characterized by both functional and structural changes in the kidney, the structural changes include GBM thickening, glomerular and tubular hypertrophy, mesangial expansion and accumulation of extracellular matrix (ECM) proteins [6] [7] [8] . On the other hand, the functional changes include microalbuminuria, proteinuria, reduction in glomerular filtration rate and elevation in both serum creatinine and blood urea nitrogen levels, where the major functional parameter of DN is microalbuminuria 9, 10 . Microalbuminuria is defined as urinary albumin excretion (UAE) rate of 20-200 µg/min (30-300 mg/24h) 11, 12 . Chronic hyperglycemia is responsible for development of DN through four biochemical pathways: advanced glycation end-products (AGEs) pathway, protein kinase C (PKC) pathway, hexosamine biosynthetic pathway (HBP) and aldose reductase (AR) pathway 13, 14 . Furthermore, abnormal activation of the renin-angiotensin system (RAS) by chronic hyperglycemia plays an important role in development of DN 15 . To illustrate, Angiotensin II (Ang II) which is the dominant effector of RAS, has a vital role in development of DN via its potent effects on renal structure and function 16 . It leads to mesangial expansion by stimulating the production of transforming growth factor-β1 (TGF-β1), a potent cytokine that stimulates the production of other growth factors as collagen and fibronectin 17, 18 . It also increases plasminogen activator inhibitor-1 (PAI-1) synthesis and inhibits the activity of mesangial cell collagenase which results in matrix accumulation 19 . Ang II also generates oxidative stress via NADPH oxidase 20 . In addition, Ang II increases glomerular permeability of protein and impairs the sizeselective function of glomerular filter by decreasing nephrin expression, a protein of the slit diaphragm implicated in pathogenesis of proteinuric conditions 21, 22 . Additionally, renin which is the rate-limiting step of RAS, can also initiate DN by stimulating the production of TGF-β1, PAI-1, fibronectin and collagen through activation of the extracellular signal regulated kinases 1 and 2 (ERK1/2) pathway in mesangial cells 23, 24 This study was conducted to assess the renoprotective effects of aliskiren-pentoxifylline combination (DRI plus xanthine derivative) and compare it with enalapril(ACEI) and valsartan (ARB) among patients with hypertension, type 2 DM and diabetic nephropathy.
SUBJECTS, MATERIALS AND METHODS

Study Design
This study is a non-randomized, prospectivecomparative study in which the renoprotective effect of aliskiren-pentoxifylline combination was evaluated and compared with enalapril and valsartan in patients with hypertension, type 2 DM and diabetic nephropathy.
Patients
Study Population and Sample Size
Participants of the study were patients with hypertension, type 2 DM and diabetic nephropathy from both genders. The sample size was sixty patients divided into three groups (each group consisted of 20 patients) according to the treatment protocol. They were selected from private clinics and UNRWA health centers in Gaza Strip.
Selection Criteria
Patients were considered eligible in this study upon meeting the following criteria: (1) 
Treatment Protocol
Patients participating in the study (60 patients) were divided into three groups (each group consisted of 20 patients) according to the treatment protocol. The first group (n=20) continued using enalapril (10-20 mg/day), the second group (n=20) was treated with valsartan (160 mg/day) instead of enalapril, whereas the third group was treated with aliskiren-pentoxifylline combination (150, 400 mg/day) also instead of enalapril. All patients used the previous drugs protocol for 9 months. Participants were able to use any oral hypoglycemic agent or insulin therapy according to physician instructions.
Methods
Hematological Analysis
Hematological analysis was performed for each patient before and at 3, 6 and 9 months of treatment. One day before the required analysis, participants were phoned and asked to fast for 12 hours. Blood samples taken from patients were sent to the laboratory to perform the required tests which included serum creatinine level and fasting plasma glucose (FPG).
Urinalysis
Urine analysis was performed for our patients before and at 3, 6 and 9 months of treatment. Two days before the visit, patients were phoned to collect their urine throughout the day (24 hours) in a suitable container. Then urine samples were sent to the laboratory to measure UAE rate.
Blood Pressure Measurement
Blood pressure was measured for all patients with a mercury sphygmomanometer. Systolic and diastolic blood pressures were measured for our patients every 3 months of treatment throughout the study period (9 months). Before measuring, patients were rested for 10 min, then BP was measured three times on the left arm. Finally, the average of the three readings was recorded for each patient.
Statistical Analysis
The collected data was analyzed using the statistical package of social science (SPSS) software package version 16. Statistical tests as frequency and distribution were done to express our data as numbers and percentages. Moreover, paired T-test was performed to compare urinary albumin excretion rates and serum creatinine levels individually in each group before and at 3, 6 and 9 months of treatment, whereas independent Ttest was used to compare aliskiren-pentoxifylline combination treated group with enalapril and valsartan treated groups for their urinary albumin excretion rates and serum creatinine levels. Significance of the association was tested at an alpha value of ≤ 0.05.
RESULTS
Characteristics of the Study Population
Participants included in this study were sixty patients divided into three groups according to the drug protocol used. The first group was treated with enalapril and included 13 (65%) males; 7 (35%) females. The age of participants was from 50 to 61 years with a mean of 55.5 ± 3.3 and they had type 2 DM from 9 to 16 years with a mean of 12.25 ± 2.35, while they had hypertension from 6 to 12 years with a mean of 8.9 ± 1.98 (table 1). The second group was treated with valsartan and included 12 (60%) males and 8 (40%) females and their age ranged from 51 to 60 years with a mean of 55.05 ± 2.6. Moreover, the patients had type 2 DM and hypertension from 8 to 14 years with a mean of 11.7 ± 2 and from 6 to 12 years with a mean of 9.1 ± 2, respectively (table 1). The third group was treated with aliskirenpentoxiphylline combination and both genders were represented equally (10 males and 10 females), their age ranged from 49 to 60 years with a mean of 55.55 ± 2.9. In addition, they had type 2 DM from 8 to 15 years with a mean of 12.05 ± 2.3, and hypertension from 7 to 13 years with a mean of 9.85 ± 2.15 (table 1). (2) show the effect of enalapril (10-20mg/day) on UAE rate and serum creatinine level. Enalapril showed no statistical significant effect (P>0.05) on UAE rate and serum creatinine level during the study period (9 months). The UAE rate was variable, it increased from 113 ± 10.679 µg/min at beginning of the study to 115 ± 9.862 µg/min after 3 months and then to 117.65 ± 6.761 µg/min after 6 months, however, it decreased back to 116.35 ± 6.564 µg/min after 9 months of the treatment. Regarding serum creatinine level, it insignificantly (P>0.05) decreased from 1.328 ± 0.052 mg/dL at baseline to 1.325 ± 0.054 mg/dL and then to 1.324 ± 0.053 mg/dL after 3 and 6 months of enalapril (10-20 mg/day) treatment, respectively. However, it increased to 1.332 ± 0.044 mg/dL after 9 months of treatment (table 2).
Effect of Drugs on Urinary Albumin Excretion
Effect of Valsartan Treatment on UAE Rate (µg/min) and Serum Creatinine Level (mg/dL) in Patients before and at 3, 6 and 9 Months of Treatment
The effect of valsartan (160 mg/day) on UAE rate and serum creatinine level is indicated in table (3) . The results show that UAE rate decreased significantly (P<0.05) only after 9 months of valsartan treatment, where it decreased from 117.95 ± 8.075 µg/min at baseline to 115.70 ± 6.736 µg/min after 9 months of treatment. On the contrary, no significant (P>0.05) decrease was shown in serum creatinine levels after 9 months of valsartan (160 mg/day) use. To illustrate, the serum creatinine level decreased from 1.326 ± 0.036 mg/dL at baseline to 1.325 ± 0.038 mg/dL after 3 months. After 6 months of treatment, it returned to the same baseline value and increased after 9 months to reach a value of 1.328 ± 0.035 mg/dL.
3.2.3.
Effect of Aliskiren-Pentoxiphylline Combination on UAE Rate (µg/min) and Serum Creatinine Level (mg/dL) in Patients before and at 3, 6 and 9 Months of Treatment Data analysis revealed a highly significant (P<0.05) reduction in both UAE rate and serum creatinine level after 6 and 9 months of aliskiren-pentoxiphylline (150, 400 mg/day) combination when compared with baseline value. The UAE rate decreased to 111.50 ± 10.405 µg/min and then to 107.70 ± 10.780 µg/min after 6 and 9 months of treatment, respectively (table 4). Concerning the serum creatinine level, it decreased from 1.319 ± 0.035 mg/dL at baseline to 1.316 ± 0.036 mg/dL and then to 1.302 ± 0.035 after 6 and 9 months of treatment, respectively (table 4).
Drugs Effect on Urinary Albumin Excretion (UAE) Rate and Serum Creatinine Level (mg/dL) in Different Groups
UAE rates among Patients Treated with Enalapril, Valsartan or Aliskiren-Pentoxiphylline Combination during the Study Period
The results in table (5) as well as figure 1 compare the effect of aliskiren-pentoxiphylline (150, 400 mg/day) combination and the effect of enalapril (10-20 mg/day) and valsartan (160 mg/day) on UAE rates. There was no significant difference (P>0.05) neither at baseline where the levels were 113.45 ± 10.679 µg/min for enalapril, 117.95 ± 8.075 µg/min for valsartan and 113.33 ± 7.631 µg/min for aliskiren-pentoxiphylline combination, nor after 3 months of treatment, as the levels were 115 ± 9.862 µg/min, 116.95 ± 8.648 µg/min and 112.55 ± 9.517 µg/min for enalapril, valsartan and aliskirenpentoxiphylline, respectively. However, a statistical significant difference (P<0.05) between the UAE rates was found after 6 and 9 months of treatment, the significance was more pronounced after 9 months (P<0.01). The UAE rates were 116.35 ± 6.564 µg/min for enalapril, 115.70 ± 6.736 µg/min for valsartan and 107.70 ± 10.780 µg/min for aliskiren-pentoxiphylline combination after 9 months of treatment.
Serum Creatinine Levels (mg/dL) among Patients Received Enalapril, Valsartan or AliskirenPentoxiphylline Combination during the Study Period
The results shown in table (6) compare the effect of aliskiren-pentoxiphylline (150, 400 mg/day) combination and the effect of enalapril (10-20 mg/day) and valsartan (160 mg/day) on serum creatinine levels. Our findings showed no statistical significant difference (P>0.05) between the serum creatinine levels at baseline in the enalapril (1.328 ± 0.052 mg/dl), valsartan (1.326 ± 0.036 mg/dl) and aliskiren-pentoxiphylline treated patients (1.319 ± 0.035 mg/dl). Similarly, the difference in serum creatinine levels continued to be insignificant even after 3 and 6 months of treatment. In contrast, the results after 9 months of enalapril (1.332 ± 0.044 mg/dl), valsartan (1.328 ± 0.035 mg/dl) or aliskiren-pentoxiphylline (1.302 ± 0.035 mg/dl) treatment demonstrated a statistical significant difference (P<0.05) among the serum creatinine levels (figure 2).
DISCUSSION 4.1. Effect of Enalapril on Urinary Albumin Excretion (UAE) Rate and Serum Creatinine Level
Abnormal activation of RAS plays a vital role in the development of DN through Ang II that is produced from Ang I via ACE, so the use of ACEIs may improve renal function in patients with DN 15, 32 . The results of our study showed insignificant reduction (P>0.05) in UAE rate and serum creatinine level among patients who used enalapril (10-20mg/day) throughout the study period (9 months). The mean UAE rate increased from 113 ± 10.679 µg/min at the beginning of the study to 116.35 ± 6.564 µg/min after 9 months of enalapril treatment. The obtained result was compatible with a study performed in Japan by Baba, 2001 . In that study, the mean UAE rate in 208 patients who received enalapril (5-20 mg/day) increased from 42 mg/day at baseline to 74 mg/day after 2 years of treatment 33 . This result was explained by inability of ACEIs to produce complete suppression of Ang II, where approximately 40% of Ang II found in the kidney is generated by ACE-independent alternate pathways such as chymase pathway, therefore its level is not inhibited completely and may return to the normal level after several days 25, 34 . However, some studies including Ravid et al., (1996) and Chan et al., (2000) reported a positive effect of enalapril on UAE rate 35, 36 . This positive effect was probably related to the high dose of the drug used (40 mg/day in Chan et al., study) or to the long period of the study (7 years in Ravid et al., study). In case of serum creatinine level, our study indicated that it increased from 1.328 ± 0.052 mg/dL at baseline to 1.332 ± 0.044 mg/dL at 9 months of treatment. This result was similar to the results of previous studies as Chan et al. (2000) and Baba (2001) . For example, Baba (2001) showed that the serum creatinine level in 208 patients who received enalapril (20 mg/day) was 0.76 ± 0.02 mg/dL at baseline. He found no significant reduction in serum creatinine level in those patients after two years of enalapril treatment 33 .
Effect of Valsartan on Urinary Albumin Excretion (UAE) Rate and Serum Creatinine Level
Although ACEIs block the conversion of Ang I to Ang II by ACE, they do not block the production of Ang II by non-ACE pathways such as chymase pathway 34 . Ang II has a vital role in the pathophysiology of DN via its interaction with the AT 1 . Concerning serum creatinine level, it was variable throughout the study period following valsartan use. It decreased from 1.326 ± 0.036 mg/dL at baseline to 1.325 ± 0.038 mg/dL after 3 months. After 6 months of treatment, it returned to the same baseline value, and then it increased to reach a value of 1.328 ± 0.035 mg/dL after 9 months. These findings were in agreement with the results obtained by many studies including Suzuki (2002) 
Effect of Aliskiren-Pentoxiphylline Combination on Urinary Albumin Excretion (UAE) Rate and Serum Creatinine Level
Despite their renoprotective effect, both ACEIs and ARBs cannot prevent the progression of DN completely because they increase plasma renin level and its activity 26, 39, 40 . Recent studies demonstrated that renin plays a key role in the development of DN by binding to (Pro)renin Receptor [(P)RR] in glomerular mesangial cells 41, 42 . The binding of renin to (P)RR stimulates the production of TGF-β, PAI-1, fibronectin, and collagen through the angiotensin-independent extracellular signal-regulated kinase 1 and 2 (ERK 1/2) pathway 23, 24, 43 . The results of this study indicate that aliskiren-pentoxiphylline (150, 400 mg/day) combination significantly (P<0.05) reduced both UAE rate and serum creatinine level after 6 and 9 months of treatment. The UAE rate decreased from 113.33 ± 7.761 µg/min at baseline to 111.50 ± 10.405 µg/min after 6 and then to 107.70 ± 10.780 µg/min after 9 months of treatment (table 4). In addition, our findings showed that aliskiren-pentoxiphylline combination had an efficient effect on renal function by decreasing the serum creatinine level significantly (P<0.05). To exemplify, serum creatinine level decreased from 1.319 ± 0.035 mg/dL at baseline to 1.316 ± 0.036 mg/dL, and then to 1.302 ± 0.035 mg/dL after 6 and 9 months of treatment, respectively (table 4) . To date, no study had evaluated the antiproteinuric effect of aliskiren-pentoxiphylline combination. For this reason our results are not compared with the results of other studies.
Moreover, our study demonstrated that the reduction produced by the combination throughout the study period (9 months) in both UAE rate and serum creatinine level was more noticeable than the reduction produced by the other drugs used in the study. To illustrate, the significant reduction in the UAE rate occurred at the 6 th month of the combination use, whereas it occurred after 9 months of valsartan use and it did not occur with enalapril over the study period ( figure 1) . Moreover, the difference between the mean serum creatinine levels among the three drugs was insignificant at baseline and after 3 and 6 months of therapy. After 9 months of therapy, the difference between the mean serum creatinine levels became significant in both enalapril/aliskiren-pentoxiphylline and valsartan/aliskirenpentoxiphylline comparisons (figure 2). The most possible explanation of these advantages for aliskiren-pentoxiphylline combination over other drugs used in the study is related to the mechanism by which both aliskiren and pentoxifylline can produce their antiproteinuric effects. The antiproteinuric effect of aliskiren was previously elucidated, while the antiproteinuric effect of pentoxifylline has been explained by three probable mechanisms. First, pentoxifylline reduces glomerular hydraulic pressure and proteinuria by decreasing the blood viscosity 44 . Second, pentoxifylline can reduce hyperfiltration and proteinuria by antagonism of adenosine (renal overproduction of adenosine is associated with hyperfiltration and proteinuria) 44 . Third, pentoxifylline reduces the production and secretion of TNF and MCP-1, which play an essential role in DN pathogenesis.
CONCLUSION
At the end of the study and based on the obtained results, we conclude the followings:
1. Aliskiren-pentoxifylline (150,400 mg/day) combination had renoprotective effect among patients with hypertension, type 2 DM and diabetic nephropathy. It significantly reduced UAE rate after 6 and 9 months of treatment and the reduction produced after 9 months of treatment was more distinct.
2. Aliskiren-pentoxifylline combination (150,400 mg/day) had positive effect on serum creatinine level, where it significantly decreased after 6 and 9 months of treatment.
3. In the valsartan (160 mg/day) treated group, there was a significant reduction in UAE rate after 9 months of treatment only, while a clear increase in UAE rate at the end of the study period was found after using of enalapril (10-20mg/day).
4. The study indicated that neither enalapril nor valsartan treatment caused an efficient effect on serum creatinine level among patients in this study.
5. The use of aliskiren-pentoxifylline combination would have better and earlier renoprotective effect than enalapril or valsartan.
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